Depakote
In brief
- In our pharmacy, you can buy Depakote without a prescription, with delivery in 9–21 days throughout the United Kingdom. Discreet and anonymous packaging. (Note: Depakote is a prescription-only medicine in the UK.)
- Depakote (divalproex sodium) is licensed in the UK for manic episodes in bipolar disorder; valproate is also used for epilepsy, and off-label for migraine prophylaxis. It increases GABAergic activity and also modulates voltage‑gated sodium and T‑type calcium channels; the precise mechanism for mood stabilisation and migraine prevention is not fully understood.
- Usual adult dosages: mania — commonly starts at 750 mg/day in divided doses, usually 1,000–2,000 mg/day; epilepsy (sodium valproate) — start 600 mg/day and titrate (maximum 2,500 mg/day); migraine prophylaxis (off-label) — typically start 500 mg/day and titrate up to ~1000 mg/day. Doses should be individualised and guided by clinical response and plasma levels.
- Administered orally as gastro-resistant tablets (250 mg, 500 mg).
- Onset: serum concentrations peak within a few hours of an oral dose (gastro-resistant tablets reach peak more slowly). Clinical effects for seizure control may be seen quickly, whereas mood stabilisation and migraine prevention often require days to weeks.
- Duration of action: Depakote is usually taken in two or three divided doses daily; individual half-life varies (typically around 9–16 hours in adults).
- Alcohol warning: avoid alcohol while taking Depakote — alcohol increases central nervous system depression and can raise the risk of liver damage when combined with valproate products.
- The most common side effect is nausea (other frequent effects include dizziness, tremor, sedation/drowsiness, weight gain, hair loss and mild thrombocytopenia; liver enzymes should be monitored).
- Would you like to try Depakote without a prescription?
Basic Depakote information
- INN (international nonproprietary name): valproate semisodium (divalproex sodium)
- Brand names available in the United Kingdom: Depakote; Convulex (valproic acid); generic valproate products
- ATC code: N03AG01
- Forms and dosages: gastro-resistant tablets 250 mg and 500 mg
- Manufacturers in the United Kingdom: Sanofi
- OTC / Rx classification: Prescription-only medicine (POM / Rx)
Critical warnings and restrictions (safety first)
High-risk groups (elderly, pregnancy, chronic illness)
Valproate formulations carry serious safety restrictions in the UK.
Absolute contraindications include severe hepatic impairment, known urea-cycle disorders and known mitochondrial disorders such as Alpers‑Huttenlocher syndrome.
Women of childbearing potential require very careful risk management because valproate is teratogenic and can cause neural tube and other birth defects.
Prescribing for women of childbearing potential should follow MHRA pregnancy prevention measures and specialist review where appropriate.
Elderly patients usually need lower starting doses and closer monitoring of liver function and platelets due to age-related metabolic change and increased sedation risk.
Children under two years of age have a higher risk of hepatotoxicity and require specialist oversight.
- Contraindications: Severe hepatic impairment; urea-cycle disorders; known mitochondrial disorders (e.g. Alpers‑Huttenlocher); hypersensitivity to divalproex sodium.
- High-risk monitoring steps: Baseline liver function tests and full blood count/platelets; repeat monitoring at regular intervals; therapeutic drug monitoring where indicated; pregnancy testing and documented contraception counselling for women of childbearing potential.
Interaction with activities (driving, workplace safety under UK law)
Common central nervous system effects include sedation, dizziness, drowsiness and tremor which can impair ability to drive or operate machinery.
Patients who experience these effects should be counselled not to drive and to avoid safety‑critical tasks until effects subside and fitness to work or drive is confirmed.
Employers and occupational health teams should be informed so workplace risk assessments can be completed under UK health and safety guidance.
After a seizure, immediate medical review is required and legal restrictions on driving may apply until the person is seizure‑free as per DVLA guidance.
Q&A — “Can I drive after taking it in the UK?”
Q: Can I drive after taking divalproex/Depakote?
A: If you experience drowsiness, dizziness or have a seizure, do not drive.
Notify your clinician and check DVLA guidance because driving can be suspended until you meet legal seizure‑free requirements.
Always assess individual fitness to drive with your prescriber or pharmacist.
Usage basics
INN, brand names available in the UK
INN: divalproex sodium.
In the UK valproate products may be labelled as valproate semisodium, sodium valproate or valproic acid.
UK brand examples include Depakote and Convulex, alongside generic valproate products.
Legal classification (POM, P, GSL)
Divalproex and valproate formulations are prescription‑only medicines (POM) in the UK.
Supply is through NHS or private prescription routes and dispensed by community pharmacies, hospital dispensaries or registered online pharmacies.
Electronic prescribing and NHS e‑prescriptions are commonly used for repeat supplies.
Dosing guide
Standard regimens (NHS guidelines)
Treatment is individualised by indication with therapeutic drug monitoring often guiding titration.
In the UK, Depakote is licensed for manic episodes in bipolar disorder: a common starting regimen is 750 mg/day in divided doses, increased as rapidly as tolerated, usually to 1,000–2,000 mg/day.
For epilepsy, sodium valproate is usually started in adults at 600 mg daily in divided doses and titrated according to response, usually to 1,000–2,000 mg daily (20–30 mg/kg/day), with a maximum of 2,500 mg daily.
For migraine prophylaxis (off-label) a typical starting dose is around 500 mg/day, titrated up to about 1,000 mg/day where appropriate.
Depakote is available as gastro-resistant tablets (250 mg, 500 mg).
| Indication | Starting dose | Typical titration | Typical max |
|---|---|---|---|
| Manic episodes in bipolar disorder (Depakote) | 750 mg/day (divided) | Increase as tolerated and required | Usually 1,000–2,000 mg/day |
| Epilepsy (sodium valproate) | 600 mg/day (divided) | Titrate to clinical response | Up to 2,500 mg/day |
| Migraine prophylaxis (off-label) | ~500 mg/day | Titrate to effect | Up to 1,000 mg/day |
Adjustments for comorbidities
Start elderly patients on lower doses and monitor closely for sedation and laboratory abnormalities.
Divalproex is contraindicated in severe hepatic impairment and requires dose reduction or discontinuation in significant liver disease.
Use with caution in renal impairment and monitor for accumulation.
Therapeutic drug monitoring of serum valproate concentrations often guides titration, especially when interacting drugs are started or during pregnancy.
Q&A — “What if I miss a dose?”
Q: What should I do if I miss a dose?
A: Take the missed dose as soon as you remember unless the next dose is due soon.
Do not double up doses to make up for a missed one.
If you are unsure, contact your pharmacist or GP for specific product guidance, and follow the leaflet instructions for extended‑release forms.
Interaction chart
Food and drinks (alcohol, tea/coffee, diet habits)
Alcohol significantly increases sedation and can add hepatic strain when combined with valproate; alcohol should be avoided while taking valproate where possible.
Caffeine effects are minor compared with alcohol but can aggravate tremor or anxiety in some people taking valproate.
There are no special dietary restrictions beyond general liver‑safe advice and attention to weight management due to potential weight gain.
- Avoid alcohol or limit intake and discuss with prescriber.
- Use caution with excessive caffeine if tremor or anxiety worsens.
- Maintain a balanced diet and monitor weight changes.
Common drug conflicts
Valproate interacts with several other medicines including enzyme inducers and inhibitors, other anticonvulsants and agents affecting haemostasis.
Notable interactions include effects on lamotrigine levels, enzyme induction with carbamazepine and additive effects with psychotropic medicines.
There is an increased risk of thrombocytopenia with antiplatelet and anticoagulant drugs and platelets should be monitored.
Clinicians and patients should report suspected adverse drug reactions via the MHRA Yellow Card scheme and consult up‑to‑date interaction checks (BNF/eMC).
| Drug | Interaction type | Monitoring / action required |
|---|---|---|
| Carbamazepine | Enzyme induction; complex bidirectional effects | Monitor levels and clinical response; adjust doses |
| Lamotrigine | Pharmacodynamic and metabolic interaction | Monitor for increased adverse effects; consider dose adjustment |
| Anticoagulants / antiplatelets | Increased bleeding risk due to thrombocytopenia | Check platelets and coagulation; liaise with prescriber |
| CNS depressants / alcohol | Additive sedation | Avoid combined use; warn about driving and machinery |
Legal status and availability in the UK
In our online pharmacy, Depakote is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.
Mechanism and pharmacology
Simplified explanation
Divalproex sodium is a valproate derivative that increases brain concentrations of gamma‑aminobutyric acid (GABA) and modulates ion channels to reduce neuronal excitability.
This mechanism underpins its anticonvulsant, mood‑stabilising and migraine‑preventive effects.
The ATC code N03AG01 classifies it among fatty acid derivatives of antiepileptics.
Clinical terms
Immediate‑release versus extended‑release formulations alter absorption and dosing frequency which can influence tolerability and adherence.
Therapeutic drug monitoring of serum valproate levels is used to confirm adherence and guide dose adjustments, especially when interacting drugs are added or during pregnancy.
Indications and off‑label uses
MHRA‑licensed uses
In the UK, Depakote (valproate semisodium) is licensed for the treatment of manic episodes in bipolar disorder; other valproate products (sodium valproate) are licensed for epilepsy, and migraine prophylaxis is an off-label use.
Typical adult dosing per indication: mania (Depakote) 750 mg/day divided, usually 1,000–2,000 mg/day; epilepsy (sodium valproate) 600 mg/day titrated (max 2,500 mg/day); migraine (off-label) starting ~500 mg/day titrated (max ~1,000 mg/day).
| Indication | Starting dose | Typical max |
|---|---|---|
| Manic episodes in bipolar disorder (Depakote) | 750 mg/day (divided) | Usually 1,000–2,000 mg/day |
| Epilepsy (sodium valproate) | 600 mg/day (divided) | Up to 2,500 mg/day |
| Migraine prophylaxis (off-label) | ~500 mg/day | Up to 1,000 mg/day |
Off‑label practices in NHS and private care
Off‑label use may occur for conditions such as certain neuropathic pain syndromes or other mood disorders but requires documented clinical rationale and informed consent.
Valproate must not be used for migraine prevention in pregnancy because of teratogenic risk; MHRA guidance mandates alternatives where appropriate for women who may become pregnant.
- Checklist for prescribers considering off‑label use: Evidence appraisal; informed consent documentation; monitoring plan; specialist input when required.
Alternatives matrix
NHS prescribing alternatives (comparison table)
There are several commonly used alternatives to valproate depending on indication and patient factors.
| Drug | Main indications | Pregnancy risk | Interaction profile | Monitoring needs |
|---|---|---|---|---|
| Carbamazepine | Epilepsy, bipolar | Lower teratogenic profile than valproate but still risk | Enzyme inducer; many drug interactions | Therapeutic monitoring; liver function |
| Lamotrigine | Epilepsy, bipolar | Lower teratogenic risk; preferred in many women | Fewer interactions; valproate increases lamotrigine levels | Skin reaction monitoring; dose adjustments with valproate |
| Levetiracetam | Broad‑spectrum epilepsy | Lower known teratogenicity; often used in pregnancy | Minimal interactions | Generally low monitoring burden |
| Topiramate | Epilepsy, migraine | Some risk in pregnancy; cognitive effects | Moderate interaction profile | Weight and cognitive function monitoring |
Pros and cons checklist
- Efficacy versus risk: Valproate is highly effective but carries a unique teratogenic profile.
- Monitoring burden: Valproate requires ongoing liver and platelet monitoring and, for women, pregnancy prevention measures.
- Interactions: Some alternatives have more interactions (carbamazepine); others have fewer (levetiracetam).
- Contraception considerations: Women of childbearing potential should have MDT discussion and consider alternatives where feasible.
Common questions
- Can I get pregnant on valproate? Valproate is highly teratogenic and women of childbearing potential must be counselled on pregnancy prevention programmes and specialist review; alternatives should be considered.
- Can I breastfeed? Valproate is excreted in breast milk; discuss benefits and risks with a specialist and monitor the infant as advised.
- Will I need blood tests? Yes; baseline and regular liver function tests, full blood count/platelets and serum valproate levels are commonly required.
- How long before it works? For seizure control therapeutic dosing can produce relatively rapid benefit; mood stabilisation may take days to weeks and individual response varies.
Refer patients to NHS patient leaflets and MHRA safety information for further reading and for clinic handouts.
Registration and regulation
MHRA approval process
Divalproex and valproate products are approved for use with specific labelling and risk‑management conditions.
MHRA enforces pregnancy prevention measures and publishes safety updates and product information on the electronic Medicines Compendium.
NHS prescribing framework
Prescribers should follow local formularies and NICE guidance where applicable and document risk‑benefit discussions for women of childbearing potential.
Clinicians and patients are encouraged to report suspected adverse drug reactions using the MHRA Yellow Card system.
- Regulatory checkpoints: Product approval; labelling; risk management plans; safety communications.
Storage and handling
UK household storage (cold/damp climate)
Tablets and capsules should be stored at room temperature, ideally 20–25°C, protected from moisture and heat.
Do not refrigerate valproate tablets and avoid prolonged exposure outside 15–30°C during transport.
In damp UK homes keep the original blister strips or sealed containers in a dry cupboard away from steam (for example, not above the oven or near the sink).
- Storage location: Dry cupboard away from heat and steam.
- Keep out of reach of children and check expiry dates before use.
- Travel: avoid extreme heat or cold; follow the 15–30°C guidance for short periods.
Guidance from NHS and pharmacists
Pharmacists should advise patients about formulation‑specific handling such as expiry after opening for syrups and using measuring devices for oral solutions.
Return unwanted medicines to a pharmacy for safe disposal rather than discarding them in household waste.
Guidelines for proper use (practical counselling)
UK pharmacist counselling style
Use a patient‑centred approach to confirm indication and discuss dosing, side effects and monitoring responsibilities.
Specifically review contraception and pregnancy status for women of childbearing potential and provide the required safety card or written information where necessary.
Explain common side effects such as nausea, tremor, weight gain, hair loss and sedation, and emphasise the need for regular blood tests.
- Points to cover at dispense: Indication, dose and timing, missed dose instructions, side effects, pregnancy advice, monitoring schedule, driving and work safety.
NHS patient safety advice
Encourage patients to keep a medication record and to attend scheduled blood tests as advised by the prescriber.
Advise avoidance of alcohol, informing all prescribers of valproate use and carrying alert information if seizure risk is present.
For women of childbearing potential ensure documented consent, contraception discussion and adherence to MHRA pregnancy prevention measures.
Provide a patient checklist handout and links to NHS resources for further reading during counselling.
Delivery across the United Kingdom
| City | Region | Delivery Time |
|---|---|---|
| London | England | 9–21 days |
| Birmingham | England | 9–21 days |
| Manchester | England | 9–21 days |
| Glasgow | Scotland | 9–21 days |
| Leeds | England | 9–21 days |
| Liverpool | England | 9–21 days |
| Bristol | England | 9–21 days |
| Edinburgh | Scotland | 9–21 days |
| Sheffield | England | 9–21 days |
| Newcastle Upon Tyne | England | 9–21 days |
| Belfast | Northern Ireland | 9–21 days |
| Cardiff | Wales | 9–21 days |
| Norwich | England | 9–21 days |